Roche/Maxygen Halt Development Of Next-Generation Pegasys Candidate
This article was originally published in The Pink Sheet Daily
End of Roche relationship has no financial impact on Maxygen, which plans an update on unpartnered Phase II neutropenia candidate MAXY-G34 for early 2008, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Ahead of AASLD, Roche’s Senior Medical Director Thommes discusses the firm’s hepatitis C pipeline with “The Pink Sheet” DAILY.
MAXY-alpha has been put on clinical hold based on Phase I observations.
Firm speculates drug could grab 20 percent to 50 percent of Neulasta’s market share.